Abstracts tagged "risk factors"

Abstract Number: 0487 • ACR Convergence 2024
The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose Felix Restrepo Suarez¹, Carlos Lorenzo¹, Inmaculada Del rincon² and Agustin Escalante¹, ¹UT Health San Antonio, San Antonio, TX, ²UT Health San Antonio, San Antonio
Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…
Abstract Number: 0991 • ACR Convergence 2024
Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations
Varinder Hans¹, Don Voaklander¹, C. Allyson Jones² and Elaine Yacyshyn², ¹University of Alberta, Edmonton, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Sarcoidosis is a granulomatous inflammatory response thought to be due to a dysregulated immune response to environmental antigens.1 The prevalence of sarcoidosis varies geographically.…
Abstract Number: 1509 • ACR Convergence 2024
Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort
Rosana Quintana¹, Guillermo Pons-Estel², Karen Roberts³, Erika S. Palacios Santillan³, Íñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Pablo Ibañez⁶, Leonel Ariel Berbotto⁷, Maria Constanza Bertolaccini⁸, Marina Laura Micelli⁹, Cecilia Pisoni¹⁰, Vitalina De Souza Barbosa¹¹, Henrique de Ataíde Mariz¹², Francinne Machado Ribeiro¹³, Luciana Parente¹⁴, Emília Sato¹⁵, Milena Mimica Davet¹⁶, Gustavo Aroca Martínez¹⁷, Fabio Bonilla-Abadía¹⁸, Gerardo Quintana López¹⁹, Reyna E. Sánchez Briones²⁰, Mario Pérez Cristóbal²¹, Luis H. Silveira Torre²², Ignacio García De La Torre²³, Ivan Morales Avendaño²⁴, Pablo Gamez-Siller²⁵, Astrid Paats²⁶, Jorge N. Cieza Calderón²⁷, Andy Armando Mendoza Maldonado²⁸, Martin Rebella²⁹, Gonzalo Silveira³⁰, John Fredy Jaramillo³¹, Monica Sanchez³², Urbano Sbarigia³³, Ashley Orillion³⁴, Federico Zazzetti³⁵, Graciela Alarcon³⁶ and Bernardo Pons-Estel³⁷, and Grupo Latino Americano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ³Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁵Galicia Health Service (SERGAS), Vigo, Spain, ⁶Servicio de Reumatología del HIGA San Martín, La Planta, Argentina, ⁷Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ⁸Servicio de Reumatologia - Hospital Angel C. Padilla, San Miguel de Tucumán, Argentina, ⁹Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹⁰CEMIC, Buenos Aires, Argentina, ¹¹Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ¹²Universidad Federal de Pernambuco, Recife, Brazil, ¹³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ¹⁶Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, ¹⁷Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ¹⁸Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ¹⁹Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²⁰División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, ²¹Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ²²Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ²³Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, ²⁴Hospital Central Dr. Ignacio Morones Prieto, Potosi, Mexico, ²⁵Servicio de Reumatologia del Hospital Universitario, "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²⁶Hospital de Clínicas I, Asunción, Paraguay, ²⁷Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, ²⁸Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ²⁹Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ³⁰Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ³¹Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, ³²Unidad Nefrologia,Hospital fernandez, CABA, Argentina, ³³Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³⁴Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ³⁵Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ³⁶The University of Alabama at Birmingham, Oakland, CA, ³⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of serious infections, which in turn, are associated with morbidity and mortality. The Systemic…
Abstract Number: 2325 • ACR Convergence 2024
Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Mikkel Ostergaard², Jette Heberg³, Zohra Faizy Ahmadzay⁴, Brigitte Michelsen⁵, Simon Horskjær Rasmussen⁶, Mehrdad Kazemi⁶, Johan Karlsson Wallman⁷, Tor Olofsson⁸, Bente Glintborg⁹, Anne Gitte Loft¹⁰, Isabel Castrejón¹¹, Ladislav Šenolt¹², Michael J. Nissen¹³, Burkhard Moeller¹⁴, Jorge Garcia¹⁵, Filipe Barcelos¹⁶, Ziga Rotar¹⁷, Katja Perdan-Pikmajer¹⁷, Catalin Codreanu¹⁸, Corina Mogosan¹⁸, Karin Laas¹⁹, Sigrid Vorobjov²⁰, Bjorn Gudbjornsson²¹, Gerdur Gröndal²¹, Dan Nordstrom²², Anna-Mari Hokkanen²³, Pawel Mielnik²⁴, Tore K. Kvien²⁵, Gökçe Kenar²⁶, Marleen Van De Sande²⁷, Merete Hetland²⁸ and Lykke Oernbjerg¹, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³Rigshospitalet Glostrup, København V, Denmark, ⁴Rigshospitalet Glostrup and Copenhagen University, Glostrup, Denmark, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Rigshospitalet Glostrup, Glostrup, Denmark, ⁷Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ⁸Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁹DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁰Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹¹Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Geneva University Hospital, Geneva, Switzerland, ¹⁴Inselspital - University Hospital Bern, Bern, Switzerland, ¹⁵Clínica Médico Ourém, Ourém, Portugal, ¹⁶Universidade Nova de Lisboa, Instituto Português de Reumatologia and Hospital CUF Descobertas, Lisbon, Portugal, ¹⁷University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁸University of Medicine and Pharmacy, Bucharest, Romania, ¹⁹East-Tallinn Central Hospital, Tallinn, Estonia, ²⁰National Institute for Health Development, Tallinn, Estonia, ²¹Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ²²Helsinki University Hospital, Helsinki, Finland, ²³Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²⁴Helse Førde, Førde, Norway, ²⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²⁶Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁷Amsterdam Institute for Infection & Immunity and Reade and Amsterdam UMC, Amsterdam, Netherlands, ²⁸Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Several predictors of treatment response to tumour necrosis factor inhibitors (TNFi) in routine care have been reported in psoriatic arthritis (PsA). However, data on…
Abstract Number: 0396 • ACR Convergence 2023
Hydroxychloroquine Is Associated with a Decreased Risk of Non-alcoholic Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Population-based, Cohort Study
Hsin-Hua Chen¹ and DER-YUAN CHEN², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Center of Rheumatology, China Medical University Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease characterized by chronic destructive arthritis and extra-articular involvement. Prior studies showed patients with RA had…
Abstract Number: 1074 • ACR Convergence 2023
Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Laura Cappelli¹, omer Kamal², Michelle Jones³, Clifton Bingham⁴ and Ami Shah⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²St. Agnes Hospital, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) can cause inflammatory arthritis (IA) of varying severity. Many patients with ICI-IA require immunosuppression beyond corticosteroids, but there is no…
Abstract Number: 1685 • ACR Convergence 2023
SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients
Zehra Kazmi¹, Carlos Lorenzo² and Agustin Escalante³, ¹University of Texas Health Science Center at San Antonio, San Antonio, TX, ²UT Heath San Antonio, Shavano Park, TX, ³UT Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: SLE patients have increased rates of HPV infection and cervical cancer. Although some factors are recognized for HPV infection in SLE, the relationship with…
Abstract Number: 2289 • ACR Convergence 2023
Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease
Fadi Kharouf¹, Juan Pablo Diaz Martinez², Dafna Gladman³ and Zahi Touma⁴, ¹University Health Network and University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…
Abstract Number: 0406 • ACR Convergence 2023
Obesity Is a Risk Factor for Poor Response to Treatment in Early Rheumatoid Arthritis – a NORD-STAR Spin-Off Study
Violetta Dubovyk¹, Gerdur Maria Grondal², Bjorn Gudbjornsson³, Espen A Haavardsholm⁴, Marte Schrumpf Heiberg⁴, Merete Hetland⁵, Kim Hørslev-Petersen⁶, Meliha Kapetanovic⁷, Alf Kastbom⁸, John Lampa⁹, Kristina Lend¹⁰, Dan Nordstrom¹¹, Michael Nurmohamed¹², Milad Rizk¹³, Annika Söderbergh¹⁴, Till Uhlig¹⁵, Mikkel Østergaard¹⁶, Ronald van Vollenhoven¹², Anna Rudin¹⁷ and Cristina Maglio¹⁸, ¹University of Gothenburg, Gothenburg, Sweden, ²Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶University of Southern Denmark, Odense, Denmark, ⁷Lund University and Skåne University Hospital, Lund, Sweden, ⁸Linköping University, Linköping, Sweden, ⁹Stockholm County, Hãsselby, Sweden, ¹⁰Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Västmanlands Hospital Västerås, Västerås, Sweden, ¹⁴Örebro University Hospital, Örebro, Sweden, ¹⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁷Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ¹⁸Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Several therapeutic options are currently available to treat rheumatoid arthritis (RA); however, the response to treatment is highly variable, and not all patients achieve…
Abstract Number: 1078 • ACR Convergence 2023
Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression
Yashswee KC¹ and Rochella Ostrowski², ¹Loyola University, Oakpark, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: Coronavirus disease 2019 (COVID-19) can have varying outcomes. Patients with chronic conditions or immunosuppression experience more severe illness. Both organ transplant recipients and patients…
Abstract Number: 1700 • ACR Convergence 2023
Incidence and Risk Factors for New Onset of Interstitial Lung Disease in Systemic Sclerosis: A EUSTAR Analysis
liubov Petelytska¹, Arthiha Velauthapillai², Lorenzo Tofani³, Eric Hachulla⁴, Ulf Müller-Ladner⁵, Elise Siegert⁶, Yannick ALLANORE⁷, Gabriela Riemekasten⁸, Christina Bergmann⁹, Radim Becvar¹⁰, Kamal Solanki¹¹, Branimir Anic¹², Simona Rednic¹³, Bojana Stamenkovic¹⁴, Lisa Stamp¹⁵, Joerg Distler¹⁶, Madelon Vonk¹⁷, Jeska de Vries-Bouwstra¹⁸, Anna Maria Hoffmann-Vold¹⁹, marco Matucci Cerinic²⁰, Oliver Distler²¹ and Cosimo Bruni²¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴University of Lille, Lille, France, ⁵Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ⁶Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁷Université Paris Cité, Paris, France, ⁸University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ⁹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ¹⁰Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ¹¹Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, ¹²Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Kišpatićeva 12, 10 000, Zagreb, Croatia, ¹³Prof Dr Simona Rednic, Cluj, Romania, ¹⁴Institut Niska Banja, Niska Banja, Serbia, ¹⁵University of Otago, Christchurch, New Zealand, ¹⁶Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁷Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁸Leiden University Medical Center, Leiden, Netherlands, ¹⁹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ²⁰Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ²¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Although prevalence of interstitial lung disease (ILD) in systemic sclerosis (SSc) and associated risk factors are established, less is known about its incidence and…
Abstract Number: 2308 • ACR Convergence 2023
The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort
Amanda King¹, Catherine Brown², Cleopatra Altenor¹, Timothy Niewold³ and Ashira Blazer³, ¹Bay Medical Centre, Castries, Saint Lucia, ²The University of the West Indies, Bridgetown, Barbados, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Poverty increases non-communicable disease risk, however its influence on systemic lupus erythematosus (SLE) burden is poorly understood. Non-White racial/ethnic groups, particularly of African origin,…
Abstract Number: 0416 • ACR Convergence 2023
Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study
Rakesh Kumar¹, Edward Lovering¹, Chanakya Kodishala², Sara Achenbach³, Diego Carvalho¹, Cynthia Crowson¹, John Davis¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester Minnesota, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Some sleep disorders (SD) are more prevalent in patients with chronic inflammatory diseases, such as Rheumatoid Arthritis (RA). However, most of the research has…
Abstract Number: 1080 • ACR Convergence 2023
Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study
Antoine Minier¹, Gilles Boire¹, Sophie ROUX¹, Nathalie Carrier² and Hugues Allard-Chamard¹, ¹Université de Sherbrooke, Sherbrooke, QC, Canada, ²CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada
Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) are used to treat a variety of inflammatory conditions ranging from rheumatoid arthritis to sarcoidosis. Paradoxical side-effects (PSE)…
Abstract Number: 1746 • ACR Convergence 2023
Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies
Tineke van Wesemael¹, Anna Svärd², Annemarie Dorjee¹, Thomas Huizinga¹, René Toes¹ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Centre for Clinical Research Dalarna, Uppsala, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].